Nefopam as a neuroprotective agent in Alzheimer's disease: network pharmacology, molecular docking, molecular dynamics simulations, and in vivo evaluation
Authors: Saini, Mayank; Hooda, Tanuj; Khatri, Ramchander; Tandey, Roshni; Lather, Amit; Bhardwaj, Hemlata; Dar, Mohammad Ovais; Kumar, Sandeep
Source journal: Naunyn-Schmiedeberg's archives of pharmacology (2026-11-20)
DOI: 10.1007/s00210-026-06118-7
Abstract
Alzheimer's disease (AD) remains a progressive neurodegenerative disorder marked by declining cognition, deteriorating memory, and behavioural abnormalities, with no disease-modifying therapy established despite decades of investigation. This study investigated whether nefopam - a non-opioid, centrally acting analgesic - could be repositioned as a neuroprotective agent against AD. An integrated strategy was adopted, combining network pharmacology, molecular docking, molecular dynamics (MD) simulation, and an in vivo assessment using a scopolamine-induced rat model. Eight crystal structures representing seven AD-relevant targets were selected for the computational work: MAOB (1GOS), OPRM1 (4DKL), GRIN1 (4KFQ), SLC6A3 (4M48), HTR2A (6A93 and 8ZMG), SLC6A4 (7LWD), and the GluN1/GluN2B NMDA receptor (3QEL). Docking was performed with Glide, binding free energies were estimated by MM-GBSA, and complexes were simulated for 100 ns with Desmond. Network pharmacology analysis revealed 90 shared targets between nefopam and AD-associated pathways, pointing toward a multi-target mode of action. Docking followed by MM-GBSA calculations indicated favourable binding of nefopam across the selected targets, with the most favourable MM-GBSA DeltaG bind values observed for HTR2A (6A93; - 65.77 kcal/mol), GRIN1 (- 58.28 kcal/mol), HTR2A (8ZMG; - 58.13 kcal/mol), and SLC6A4 (- 57.65 kcal/mol). Subsequent MD simulations indicated stable binding behaviour for SLC6A3 (4M48), HTR2A (6A93), and SLC6A4 (7LWD); GRIN1 (4KFQ) and MAOB (1GOS) displayed moderate stability, whereas HTR2A (8ZMG) showed instability at the protein level despite the ligand remaining reasonably well retained. In the in vivo phase, nefopam produced a dose-dependent improvement in neurobehavioural outcomes across the different assessment points. Biochemical analysis further showed a marked decline in MDA levels together with a significant rise in SOD and CAT activity, reflecting a meaningful antioxidant response. These findings suggest that nefopam exerts neuroprotective, antioxidant, and cognition-improving effects in the scopolamine-induced model of cognitive impairment, possibly involving serotonergic, glutamatergic, and monoaminergic signalling routes. Additional in vitro, mechanistic, and clinical research is needed before its repurposing for AD can be therapeutically confirmed.
Related topics
Related open access articles
- Development and Validation Molecular Docking Analysis of Human serum albumin (HSA)
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- Curcumin and pipernonaline to curb diabetes the natural way: A molecular modeling, docking and dynamics simulation study
- DENSITY FUNCTIONAL THEORY ANALYSIS AND MOLECULAR DOCKING EVALUATION OF 8-CHLOROQUINOLINE 2-CARBALDEHYDE
- Thermochemical, DFT, Molecular Docking and Pharmacokinetic Studies of Methyl β-D-galactopyranoside Esters
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.